Cinda Biotech (01801)'s product revenue in the first quarter exceeded 3.8 billion yuan, up more than 50% year-on-year

Zhitong Finance App News, Cinda Biotech (01801) announced that in the first quarter of 2026, the company recorded product revenue of more than RMB 3.8 billion, an increase of more than 50% over the previous year. This strong momentum confirms the successful implementation of the company's “two-wheel drive” strategy. The company's leading position in the field of oncology is becoming more and more prominent. Five new tyrosine kinase inhibitors (TKIs) were added to the National Medical Insurance Drug List (NRDL) and achieved rapid release. At the same time, the comprehensive product line has become a strong emerging driving force for the company's revenue growth, mainly due to the excellent performance of core products such as Xinermei® (Maxidopeptide injection), Cinpirac® (tolecimab injection), and Cinpimin® (teturozumab N01 injection).

Strong performance in the first quarter of 2026 strengthened confidence that the company's revenue will continue to grow rapidly, further consolidating the company's high growth and certainty as a leading biopharmaceutical company in China. At the same time, the company continues to promote global innovation, opening up room for continuous growth in corporate value. The company is promoting three high-value potential molecules — IBI363 (PD-1/IL-2α-Biased bispecific antibody), IBI343 (CLDN18.2ADC), and IBI324 (VEGF/ANG2 bispecific antibody) — that have entered or are about to enter global multi-center phase III clinical research, and continue to step up early innovation to promote early global clinical development of next-generation oncology, cardiovascular and metabolic (CVM), autoimmunity and ophthalmology pipelines. Looking forward to the future, the continued steady expansion of the company's domestic business scale and the acceleration of the global innovation pipeline will steadily push the company to achieve its long-term vision of “becoming a world-class biopharmaceutical company”.